Trials / Completed
CompletedNCT03206970
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study was to evaluate the efficacy of zanubrutinib in participants with centrally confirmed relapsed or refractory MCL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib | Administered as specified in the treatment arm. |
Timeline
- Start date
- 2017-03-02
- Primary completion
- 2019-02-15
- Completion
- 2020-09-08
- First posted
- 2017-07-02
- Last updated
- 2024-10-26
- Results posted
- 2020-05-13
Locations
13 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03206970. Inclusion in this directory is not an endorsement.